Yarrow Bioscience completes VYNE merger, begins Phase 2a/2b trial Jul 27, 2026 07:00AM
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Jul 27, 2026 07:00AM